创新药ETF国泰（517110）涨超1.1%，政策支持或促行业估值修复

Group 1 - The core viewpoint of the article highlights the recent initiatives by the National Healthcare Security Administration (NHSA) to support innovation in pharmaceuticals and medical devices through new pricing policies and mechanisms aimed at fostering genuine and differentiated innovation [1] - NHSA has held two meetings to discuss these new measures, which include the establishment of unified pricing for new medical services and the exploration of a pricing mechanism for newly launched drugs [1] - Since the approval of measures to support high-end medical device innovation by the National Medical Products Administration in June 2025, there has been a clear trend in top-level design favoring innovation in medical devices, with expectations for more supportive policies in the future [1] Group 2 - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects listed companies involved in the research and production of innovative drugs from the A-share market, covering various fields such as chemical pharmaceuticals, traditional Chinese medicine, and biological products [1] - The index focuses on companies with high research and development investment and innovation capabilities, aiming to reflect the overall performance of China's innovative drug industry, with an emphasis on growth and industry representation [1] - Investors without stock accounts can consider the Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiated Link C (014118) and Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiated Link A (014117) [1]